SCHEMBL208932

SCHEMBL208932

NC(O)CCCC(N)C(=O)O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSR P00390 2/20 0.60
ARG2 P78540 4/20 0.54
ARG1 P05089 3/20 0.54
CYP1A2 P05177 3/20 0.52
GRM8 O00222 1/20 0.52
GRM6 O15303 1/20 0.52
GRIN2D O15399 1/20 0.52
GRIN3B O60391 1/20 0.52
GRIK1 P39086 1/20 0.52
GRM5 P41594 1/20 0.52
GRIA1 P42261 1/20 0.52
GRIA2 P42262 1/20 0.52
GRIA3 P42263 1/20 0.52
SLC1A3 P43003 1/20 0.52
SLC1A2 P43004 1/20 0.52
SLC1A1 P43005 1/20 0.52
GRIA4 P48058 1/20 0.52
GRIN1 Q05586 1/20 0.52
GRIN2A Q12879 1/20 0.52
GRIK2 Q13002 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19758974 1.00 GSR (0.60) GSRARG2ARG1CYP1A2GRM8
SCHEMBL208933 1.00 GSR (0.60) GSRARG2ARG1CYP1A2GRM8
SCHEMBL29387596 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL15987065 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL17323357 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL29291 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL29289 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL10135848 0.89 GSR (0.71) GSRARG2ARG1CYP1A2GRM8
SCHEMBL3534047 0.85 GSR (0.60) GSRARG2ARG1CYP1A2GRM8
SCHEMBL25661160 0.85 GSR (0.60) GSRARG2ARG1CYP1A2GRM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1672 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230383291-A1 PEPTIDE-BASED TRANSDUCTION OF NON-ANIONIC POLYNUCLEOTIDE ANALOGS FOR GENE EXPRESSION MODULATION FELDAN BIO INC. (CA) 2023-11-30 US claimed
EP-2822958-B1 ANTIMICROBIAL PEPTIDES ROBERT BOSCH GES FUER MEDIZINISCHE FORSCHUNG MBH (DE) 2018-12-19 EP claimed
US-20170073371-A1 ANTIMICROBIAL PEPTIDES ROBERT BOSCH GES FÜR MEDIZINISCHE FORSCHUNG MBH (DE) 2017-03-16 US claimed
EP-2518080-B1 Antibiotic peptides AMP THERAPEUTICS GMBH (DE) 2016-05-18 EP claimed
US-20150344524-A1 MODIFIED APIDAECIN DERIVATIVES AS ANTIBIOTIC PEPTIDES UNIVERSITAET LEIPZIG (DE) 2015-12-03 US claimed
US-20150087579-A1 ANTIMICROBIAL PEPTIDES ROBERT BOSCH GENSELLSCHAFT FÜR MEDIZINISCHE FORSCHUNG MBH (DE) 2015-03-26 US claimed
EP-2822958-A1 ANTIMICROBIAL PEPTIDES Robert Bosch Gesellschaft MbH Für Medizinische Forschung (DE) 2015-01-14 EP claimed
WO-2013132005-A1 ANTIMICROBIAL PEPTIDES ROBERT BOSCH GESELLSCHAFT FÜR MEDIZINISCHE FORSCHUNG MBH (DE) 2013-09-12 WO claimed
EP-2170928-B1 ANTIBIOTIC PEPTIDES AMP THERAPEUTICS GMBH (DE) 2013-07-03 EP claimed
EP-2518080-A2 Antibiotic peptides AMP-Therapeutics GmbH & Co. KG (DE) 2012-10-31 EP claimed
WO-2006039527-A1 MACROCYCLIC SH2 DOMAIN BINDING INHIBITORS GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2006-04-13 WO claimed
US-6977241-B2 SH2 domain binding inhibitors THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH & HUMAN SERVICES (US) 2005-12-20 US claimed
US-20040048788-A1 Sh2 domain binding inhibitors DEPARTMENT OF HEALTH AND HUMAN SERVICES, UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, OF THE 2004-03-11 US claimed
EP-1383792-A2 SH2 DOMAIN BINDING INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-01-28 EP claimed
WO-2004003005-A2 SH2 DOMAIN BINDING INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2004-01-08 WO claimed
EP-1295891-A1 NUCLEOSIDE DERIVATIVES Japan Science and Technology Corporation (JP) 2003-03-26 EP claimed
WO-2002016407-A2 SH2 DOMAIN BINDING INHIBITORS THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2002-02-28 WO claimed
EP-1163262-A1 PHENYLALANINE DERIVATIVES THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2001-12-19 EP claimed
WO-2000056760-A1 PHENYLALANINE DERIVATIVES THE UNITED STATES OF AMERICA, REPRESENTED BY SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2000-09-28 WO claimed
EP-0089886-B1 PROCESS FOR THE PREPARATION OF A FREE ALPHA-L-AMINO ACID CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 1988-10-12 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048788-A1 Sh2 domain binding inhibitors ACP1, PHLPP1, SORBS1 GSR 4350/4885ARG2 3837/4885ARG1 3216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.